{ "@context": "https://schema.org", "@type": "Dataset", "name": "Boise Standard Entity: car-t.bmshealthcare.jp", "url": "https://boisestandard.org/web/car-t-bmshealthcare-jp", "identifier": "bs-5ff4398f", "datePublished": "2026-07-11T15:16:28.974710+00:00", "description": "Boise Standard machine-readable entity profile for car-t.bmshealthcare.jp. Schema.org coverage graph, six-layer topology fingerprint, ratio signals, Root-LD anchor. Full provenance.", "license": "https://creativecommons.org/publicdomain/zero/1.0/", "isAccessibleForFree": true, "creator": { "@type": "Organization", "name": "Boise Standard", "url": "https://boisestandard.org" }, "about": { "@type": "WebSite", "url": "https://www.car-t.bmshealthcare.jp/", "name": "CAR T療法の総合情報サイト Information Hub for CAR T-cell Therapy｜ブリストル・マイヤーズ スクイブ株式会社" }, "variableMeasured": [ { "@type": "PropertyValue", "name": "federationId", "value": "bs-5ff4398f" }, { "@type": "PropertyValue", "name": "schemaTypes", "value": "" }, { "@type": "PropertyValue", "name": "schemaCoverageScore", "value": "0.0" }, { "@type": "PropertyValue", "name": "topologyFingerprint", "value": "computed" }, { "@type": "PropertyValue", "name": "topologyModelVersion", "value": "1.0.0" }, { "@type": "PropertyValue", "name": "textLengthCategory", "value": "very_long" }, { "@type": "PropertyValue", "name": "typeTokenRatio", "value": "0.1462" }, { "@type": "PropertyValue", "name": "nonAsciiRatio", "value": "0.5595" }, { "@type": "PropertyValue", "name": "hapaxLegomenaRatio", "value": "0.0674" }, { "@type": "PropertyValue", "name": "javascriptSurfaceRatio", "value": "0.0" }, { "@type": "PropertyValue", "name": "navRatio", "value": "0.507" }, { "@type": "PropertyValue", "name": "securityLabel", "value": "STRONG" }, { "@type": "PropertyValue", "name": "freshnessLabel", "value": "CURRENT" }, { "@type": "PropertyValue", "name": "interiorPagesCrawled", "value": "36" }, { "@type": "PropertyValue", "name": "mintedAt", "value": "2026-07-11T15:16:28.974710+00:00" }, { "@type": "PropertyValue", "name": "specVersion", "value": "Root-LD v1.0" }, { "@type": "PropertyValue", "name": "entityType", "value": "domain" }, { "@type": "PropertyValue", "name": "detectedLanguage", "value": "ja" }, { "@type": "PropertyValue", "name": "hasGeo", "value": "False" }, { "@type": "PropertyValue", "name": "hasAtomicAnswer", "value": "False" } ], "root_ld": { "anchor": { "uuid": "5ff4398f-e43d-444c-b98c-e5d83eca04a3", "federation_id": "bs-5ff4398f", "sequence": 0, "content_hash": "9a0bf718b523459b3bc1e6ecfd1b3ce4c4ea748f7ad82e842abfa147a9112708", "primary_source": "https://www.car-t.bmshealthcare.jp/", "source_verified": true, "generation_method": "crawl_extract_v1", "spec_version": "1.0", "queued_at": "2026-05-26T20:35:49.688622+00:00", "minted_at": "2026-07-11T15:16:28.974710+00:00" }, "body": { "domain": "car-t.bmshealthcare.jp", "canonical_url": "https://www.car-t.bmshealthcare.jp/", "tld": "jp", "slug": "car-t-bmshealthcare-jp", "status_code": 200, "redirect_chain": [], "response_time_ms": 6689, "ssl_valid": true, "server_header": "Apache", "title": "CAR T療法の総合情報サイト Information Hub for CAR T-cell Therapy｜ブリストル・マイヤーズ スクイブ株式会社", "h1": "", "meta_description": "CAR T細胞療法とヒトCD19を標的とするブレヤンジ®および多発性骨髄腫（MM）のB細胞成熟抗原（BCMA）を標的とするアベクマ®の情報を医療関係者向けに提供しています。", "lang_declared": "ja", "schema_types": [], "schema_score": 0.0, "schema_prop_count": 0, "schema_gap_list": [], "top_semantic_words": [ "car", "transcend", "cell", "url", "dlbcl", "bms", "healthcare", "login", "lymphoma", "myers", "nhl", "med", "grade", "mcl", "information", "times", "code", "doccheck", "inami", "therapy", "hub", "otemachi", "bristol", "squibb", "affiliate", "subsidiary", "foot", "note", "heading", "hosp", "error", "success", "diffuse", "fol", "breyanzi", "nos", "ecog", "end", "guide", "patients" ], "ratio_signals": { "schema_density": 0.0, "nav_ratio": 0.507, "content_to_structure_ratio": 0.031337, "external_tld_diversity": 2, "self_declaration_coherence": 0.0556, "schema_to_navigation_alignment": 0.0, "javascript_surface_ratio": 0.0, "url_depth_distribution": { "depth_0": 2, "depth_1": 27, "depth_2": 7, "depth_3plus": 35 } }, "semantic_html_ratio": 0.0, "javascript_surface_ratio": 0.0, "img_alt_coverage": 0.0, "robots_complexity_score": 0, "ariadne_blocked": false, "security_label": "STRONG", "https_enforced": true, "freshness_label": "CURRENT", "tld_starjet_url": "https://boisestandard.org/registry/tld/ledger/jp", "schema_starjet_urls": [], "native_text_sample": "CAR Tとは\nブレヤンジ\nアベクマ\n動画\n患者向け資材\n適格患者・紹介フォーム\n治療施設を探す\n\nWEBセミナー\n\nサイトマップ\n\nCONTACT \n\nBMS HEALTHCARE \n\n新規会員登録\n\nブレヤンジ®の「効能、効果又は性能 」一部変更のお知らせ\n\n \n\n再発又は難治性のマントル細胞リンパ腫＊および再発又は難治性の辺縁帯リンパ腫＊に対する効能、効果又は性能の一部変更について承認されました。詳細は最新の電子添文をご参照ください。\n\n＊ ただし、CD19抗原を標的としたキメラ抗原受容体発現T細胞輸注療法の治療歴がない患者に限る。\n\nREAD MORE\n\n重要なお知らせ\n\nコンテンツ更新情報\n\n2026.04.03\n\n「ブレヤンジ静注」の効能、効果又は性能 一部変更のお知らせ\n\n2026.01.13\n\n「アベクマ点滴静注」使用上の注意改訂のお知らせ\n\n2025.03.05\n\n「アベクマ点滴静注」電子添文改訂のお知らせ\n\n2025.03.05\n\n「ブレヤンジ点滴静注」電子添文改訂のお知らせ\n\nFind a Clinic\n\n治療施設検索\n \n\nブレヤンジとアベクマのCAR-T細胞療", "topology_fingerprint_version": "1.0.0", "entity_type": "domain", "geo": { "address": "", "latitude": null, "longitude": null, "place_id": "", "category": "", "jurisdiction_path": "", "provenance_source": "", "fetched_at": "" }, "atomic_answer": "" }, "recursive": { "edges": [], "appended_at": [], "edge_count": 0 } }, "topology_fingerprint_summary": { "model_version": "1.0.0", "text_length_category": "very_long", "raw_text_length": 127247, "extracted_text_hash": "1c369059648539f2d8171461053f09f24ac985e1d460115ebb17d3b2e7f96f0d", "detected_language": "ja", "entity_type": "domain", "type_token_ratio": 0.146209, "non_ascii_ratio": 0.559518, "character_entropy": 5.424599, "hapax_legomena_ratio": 0.067353, "hapax_to_type_ratio": 0.460663, "comma_to_period_ratio": 0.0585, "repetition_score": 0.932647 }, "schema_graph_summary": { "declared_types": [], "parent_types": [], "sibling_types": [], "child_types": [], "negative_space": [ "Action", "BioChemEntity", "CreativeWork", "Event", "Intangible", "MedicalEntity", "Organization", "Person", "Place", "Product" ] } }